Exactly! Thank you for stating this. I don’t understand why this comes up. Cytodyn owners the drug, Incelldx is a diagnostic company that developed a test that identifies the markers that cytodyn’s drug works on. They complement each other and are part of how a platform is developed. Cytodyn will never own everything related to CCR5. What is good for Bruce’s company is good for Cytodyn. As for Nader stating they do not need development, I think he was referring to actual development of leronlimab, which is already developed. They have never indicated they intent to develop new drugs or variations of leronlimab. It has been very clear that Cytodyn is aggressively pursuing any indication opportunities, even if those trials are sponsored by other companies or countries.